A randomized phase II study of docetaxel or pemetrexed with or without the continuation of gefitinib after disease progression in elderly patients with non-small cell lung cancer harboring EGFR mutations (JMTO LC12-01)

Kazuhiro Asami¹ | Masahiko Ando² | Takashi Nishimura³ | Takashi Yokoi⁴ | Atsuhisa Tamura⁵ | Koichi Minato⁶ | Masahide Mori⁷ | Fumitaka Ogushi⁸ | Akiyoshi Yamamoto⁹ | Hiroshige Yoshioka¹⁰ | Masaaki Kawahara¹¹ | Shinji Atagi¹²

¹Asami Naika Clinic, Tokyo, Japan
²Department of Advanced Medicine, Nagoya University Hospital, Nagoya, Japan
³Department of Respiratory Medicine, Kyoto Katsura Hospital, Kyoto, Japan
⁴Department of Thoracic Oncology, Hyogo College of Medicine, Hyogo, Japan
⁵Department of Center for Pulmonary Diseases, Tokyo National Hospital, Tokyo, Japan
⁶Department of Respiratory Medicine, Gunma Prefectural Cancer Center, Gunma, Japan
⁷Department of Thoracic Oncology, National Hospital Organization Osaka Toneyama Medical Center, Osaka, Japan
⁸Department of Respiratory Medicine, Kochi National Hospital, Kochi, Japan
⁹Department of Respiratory Medicine, Takamatsu Red Cross Hospital, Kagawa, Japan
¹⁰Department of Thoracic Oncology, Kansai Medical University Hospital, Osaka, Japan
¹¹Department of Respiratory Medicine, KKR Otemae Hospital, Osaka, Japan
¹²Department of Thoracic Oncology, National Hospital Organization Kinki-Chuo Chest Medical Center, Osaka, Japan

Correspondence
Kazuhiro Asami, Asami Naika Clinic, 5-5-3 Nakanokami-cho, Hachioji city, Tokyo 192-8555, Japan.
Email: asami@asami-clinic.com

Abstract

Background: Gefitinib (G) is a recommended molecular-targeted agent for elderly patients with epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC). Docetaxel (Doc) and pemetrexed (Pem) have similar efficacies, and either is often used as the sole agent during treatment. The efficacy of continuing G after progressive disease (PD) develops has been reported. It remains unclear whether the continuation of G in combination with a single cytotoxic agent beyond PD is beneficial for elderly patients. Here, we conducted a randomized phase II study to assess the efficacy and safety of cytotoxic chemotherapy with G for elderly patients with progressive EGFR-mutant NSCLC.

Methods: Elderly patients with EGFR-mutant NSCLC with PD previously treated with G were enrolled. Patients received Pem 500 mg/m² or Doc 60 mg/m² every 21 days and were randomly assigned to receive chemotherapy with 250 mg G (G+ Doc/Pem arm) or without G (Doc/Pem arm) until further disease progression or unacceptable toxicity.

Results: This trial was terminated early owing to slow accrual. A group of 22 patients underwent analysis. The primary endpoint, progression-free survival (PFS), was significantly longer in the G + Doc/Pem arm (median: 1.6 months vs. 5.6 months, hazard ratio = 0.40, 95% CI: 0.16–0.99, p = 0.0391). Adverse events ≥ grade 3 were more frequent in the G + Doc/Pem arm (45.5% vs. 90.9%, p = 0.032).

This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

© 2022 The Authors. Thoracic Cancer published by China Lung Oncology Group and John Wiley & Sons Australia, Ltd.

Thoracic Cancer. 2022;13:1827–1836. wileyonlinelibrary.com/journal/tca 1827
INTRODUCTION

Lung cancer is the leading cause of cancer death worldwide.\(^1\) Approximately 70\% of patients with lung cancer patients are diagnosed with advanced non-small cell lung cancer (NSCLC), and the prevalence and lung cancer mortality have been increasing in Japan.\(^5\) These increases are more prominent in elderly Japanese patients because of its super-aging society; elderly patients aged \(\geq 70\) years account for 75\% of lung cancer deaths.\(^5\)

Docetaxel (Doc) is a third-generation cytotoxic agent and recommended monotherapy regimen for elderly patients with advanced NSCLC.\(^6\) Large-scale trials to demonstrate the efficacy of pemetrexed (Pem) monotherapy in elderly patients with advanced NSCLC have not yet been performed. However, the efficacy of Pem in elderly patients is expected to be similar to that of Doc. Based on the findings of a subset analysis of a phase III study on Pem and Doc\(^7\) and a review of two randomized studies on Pem,\(^8\) time to progression, overall survival (OS), and toxicity profiles were favorable for Pem. Therefore, Doc and Pem are both recommended for the treatment of elderly Japanese patients with advanced NSCLC.

Gefitinib (G) is a first-generation epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) with a demonstrated strong efficacy in patients harboring active EGFR mutations.\(^8\)\(^11\) Phase II studies showed the utility and efficacy of G as first-line therapy for elderly patients with advanced EGFR-mutant NSCLC.\(^1\)\(^2\)\(^,\)\(^3\)

Previous studies reported the utility and safety of combination therapy with first-generation EGFR-TKIs, such as G and erlotinib, plus Doc or Pem for advanced NSCLC.

Manegold et al. assessed the feasibility of combination therapy with G and Doc in patients with advanced NSCLC.\(^1\)\(^4\)\) Fifteen patients each were recruited for different doses of G. The most common observed adverse events (AEs) were consistent with the known profiles of G, and dose-limiting toxicities were not detected. Therefore, the combination of G and Doc is feasible and acceptable for patients with NSCLC.

Yoshimura et al. assessed the efficacy and toxicity of combination therapy with G and Pem in elderly patients (\(\geq 70\) y) with previously untreated NSCLC and a performance status (PS) of 0–1.\(^1\)\(^5\) A total of 44 eligible patients were enrolled. The overall response rate (RR) was 29\%, with 48\% for stable disease (SD). The median progression-free survival (PFS) and OS were 8 (95\% confidence interval [CI]: 6.2–10.6) and 12 months (95\% CI: 5.6–17.5) for all patients, respectively. The most common hematological AEs were lymphopenia and anemia, while the most common nonhematological AEs were fatigue, hyperglycemia, and dyspnea. These findings suggested that the combination of one cytotoxic drug plus G is an acceptable regimen for elderly patients with advanced NSCLC.

Although the efficacy of G for advanced EGFR-mutant NSCLC has been demonstrated, most patients relapse after approximately 1 year. Some EGFR-mutant NSCLCs acquire resistance to G and show accelerated disease progression after its discontinuation.\(^1\)\(^6\)\(^,\)\(^7\)\) The continuation of G combined with a single cytotoxic drug to reduce the risk of accelerated disease progression is a promising strategy for elderly patients with EGFR-mutant NSCLC.

Therefore, we conducted a prospective phase II study to evaluate the efficacy and safety of the continuation of G combined with Doc or Pem in elderly patients with EGFR-mutant NSCLC.

METHODS

Inclusion criteria

We enrolled patients aged \(\geq 70\) years with adequate major organ functions and cytologically- or histologically-confirmed active EGFR-mutant stage IIIB or IV NSCLC, including the exon 19 deletion mutation or L858R, after the confirmation of radiological disease progression during G therapy of at least 3 months. They were required to have a measurable or assessable disease as defined by the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 and a PS of 0 or 1 by the Eastern Cooperative Oncology Group (ECOG) criteria. Patients with a complete response (CR), partial response (PR), or SD for >6 months while being treated with G were eligible.

Exclusion criteria

We excluded patients who were advised to switch to platinum-doublet chemotherapy or patients with any of the following: a history of interstitial pneumonia and pre-existing idiopathic pulmonary fibrosis pneumonia, active infectious disease, and uncontrolled pleural or cardiac effusion.

The study protocol was approved by each institution’s ethics review board, and the study was conducted in accordance with the Declaration of Helsinki and Good Clinical Practice guidelines. The study was registered with University Hospital Medical Information Network Clinical Trials Registry (ID, UMIN 000007765). All patients provided written informed consent before enrollment.
Study design

The study design is shown in Figure 1. Eligible patients were randomized in a 1:1 ratio to receive docetaxel (Doc) or pemetrexed (Pem) therapy alone (chemotherapy arm) or the continuation of gefitinib (G) plus Doc or Pem (combination therapy arm). Doc, docetaxel; G, gefitinib; Pem, pemetrexed; NSCLC, non-small cell lung cancer; ECOG PS, Eastern Cooperative Oncology Group performance status; PFS, progression-free survival; ORR, objective response rate; DCR, disease control rate; OS, overall survival.

Treatment assessments

The primary endpoint was PFS. The secondary endpoints were response rates (CR plus PR), disease control rates (DCR: CR plus PR plus SD), OS, and toxicity profiles. PFS was defined as the period between the date of randomization to the date of objective progression or death. OS was defined as the period between the date of randomization to the date of death due to any cause.

SD had to meet the criteria of SD at least once >6 weeks after randomization. All enrolled patients were evaluated for safety and assessed for toxicity before each cycle using the Common Terminology Criteria for Adverse Events Version 4.03. They underwent full-body computed tomography every 6 weeks until PD was achieved, and they were examined using RECIST version 1.1.

Statistical analysis

With PFS as the primary endpoint, Shoenfeld’s formula\textsuperscript{18} was used to calculate the sample size for this study. The PFS of Doc and Pem in previous studies was approximately 2.0 months as second-line therapy and 5.5 months as first-line therapy for elderly patients with NSCLC.\textsuperscript{6,19} A randomized phase III trial of Pem versus Doc in previously treated patients with advanced NSCLC reported the same PFS of 2.9 months for each treatment arm.\textsuperscript{19} The PFS of patients who received epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) plus chemotherapy was 7.0 and 8.0 months, respectively for patients who received...
EGFR-TKIs plus Pem.\(^{14,15}\) We set a 6-month PFS as a primary endpoint, which is two months longer than that for chemotherapy including Doc or Pem alone, as suggested in the aforementioned trials. This study was designed to detect a prolonged PFS with G + Doc/Pem combination therapy with an 80% power using the log-rank test with a one-sided \(\alpha\) of 5%, an accrual period of 12 months, and a follow-up period of 24 months. The estimated minimum accrual was 28 cases. Assuming a patient dropout rate of approximately 10%, the sample size was 30 patients in each arm. Central randomization was performed using the minimization method of balancing institution and brain metastasis (yes or no).

PFS and OS were estimated using the Kaplan–Meier method, and the \(p\)-value for differences between curves was calculated using the log-rank test. Hazard ratios and associated 95% CIs between the treatment arms were calculated. Differences in RRs and frequency of AEs, and the associated 95% CIs were calculated and compared with Fisher’s exact test. A \(p\)-value <0.05 was considered statistically significant. Statistical analyses were performed using the software SAS version 9.2 (SAS Institute).

### TABLE 1  Patient characteristics

| Characteristic                        | No. of patients (%) | Chemotherapy\(^a\) arm (\(n = 11\)) | Gefitinib plus chemotherapy\(^a\) arm (\(n = 11\)) |
|---------------------------------------|---------------------|-------------------------------------|--------------------------------------------------|
| Median age, years (range)             |                     | 76 (72–84)                          | 78 (70–86)                                       |
| Sex                                   |                     |                                    |                                                  |
| Male                                  | 1 (10)              | 1 (10)                              |                                                  |
| Female                                | 10 (90)             | 10 (90)                             |                                                  |
| Performance status (ECOG)             |                     |                                    |                                                  |
| 0                                     | 6 (55)              | 4 (36)                              |                                                  |
| 1                                     | 5 (45)              | 7 (64)                              |                                                  |
| Stage                                 | IV                  | 11 (100)                            | 11\(^b\) (100)                                   |
| Histology                             | Adenocarcinoma      | 11 (100)                            | 11 (100)                                         |
| Smoking history                       |                     |                                    |                                                  |
| Never smoker                          | 9 (82)              | 8 (73)                              |                                                  |
| Ex-smoker                             | 2 (18)              | 3 (27)                              |                                                  |
| EGFR mutation status                  |                     |                                    |                                                  |
| Exon 19 deletion                      | 5 (45)              | 6 (55)                              |                                                  |
| Exon 18                               | 6 (55)              | 5 (45)                              |                                                  |
| Brain metastasis                      |                     |                                    |                                                  |
|                                       | 3 (27)              | 3 (27)                              |                                                  |
| Responses to gefitinib                |                     |                                    |                                                  |
| PR                                    | 7 (64)              | 9 (82)                              |                                                  |
| SD                                    | 4 (36)              | 2 (18)                              |                                                  |
| Median duration of gefitinib administration (months), range | | 10.4 (4.8—66.3) | 9.6 (7.6—37.1) |
| Administration period of gefitinib (months) | | Once daily 7 (64) | 9 (82) |
|                                        | Others 4\(^c\) (36) | 2\(^d\) (18) |                                                  |
| Chemotherapy agent                    |                     |                                    |                                                  |
| Docetaxel                             | 3 (27)              | 5 (45)                              |                                                  |
| Pemetrexed                            | 8 (73)              | 6 (55)                              |                                                  |

Abbreviation: ECOG, Eastern Cooperative Oncology Group; EGFR, epidermal growth factor receptor; PR, partial response; SD, stable disease.

\(^a\)Docetaxel or pemetrexed.

\(^b\)Postoperative recurrences occurred in three patients.

\(^c\)Alternate-day administration (1 patient) and once every three days (1 patient).

\(^d\)Alternate-day administration (2 patients), once every three days (1 patient), and twice a week (1 patient).
RESULTS

Patient characteristics

This study was closed in early July 2016 because of poor accrual. Between April 2012 and August 2015, a preliminary analysis involving 22 patients randomly assigned to receive Doc or Pem alone or the continuation of G + Doc/Pem was conducted. The patient and disease baseline characteristics are shown in Table 1. All registered patients received at least one cycle of chemotherapy. Two patients in each arm failed to meet the inclusion criteria. All the patients had adenocarcinomas and activated EGFR mutations, including exon 19 deletion and L858R.

Three patients in the Doc/Pem arm and five in the G + Doc/Pem arm received Doc, while eight patients in the Doc/Pem arm and six in the G + Doc/Pem arm received Pem. More than 50% of enrolled patients were administered G once daily and all patients continued G on the same schedule as before enrollment in each treatment arm.

Ten patients in the Doc/Pem arm and four in the G + Doc/Pem arm discontinued the protocol treatment due to disease progression, which was observed after one cycle of chemotherapy in two out of the 10 patients (18%) in the Doc/Pem arm. Nonhematological AEs did not resolve until the next treatment cycle in one patient in the Doc/Pem arm. In the G + Doc/Pem arm, protocol therapy was discontinued in seven patients because of their requests or judgments by the attending physician based on a reduced PS due to nonhematological AEs (fatigue, diarrhea, and anorexia).

The median number of chemotherapy treatment cycles was two for each chemotherapy group in the Doc/Pem arm, six for the Doc group, and four for the pemetrexed group in the G + Doc/Pem arm (Table 2).

| Treatment agents and their administration | Chemotherapy* arm (n = 11) | Gefitinib plus chemotherapy* arm (n = 11) |
|------------------------------------------|---------------------------|-----------------------------------------|
| Docetaxel                                | Median treatment cycle (range) 2 (1–2) | 6 (1–9) |
| Pemetrexed                               | Median treatment cycle (range) 2 (1–18) | 4 (1–10) |
| Duration period of gefitinib             | Median months (range) NA | 2.9 (0.2–9.2) |

Abbreviation: NA, not applicable.

*Docetaxel or pemetrexed.
The median follow-up time was 8.8 months. The median PFS and OS were 1.6 months (95% CI: 1.2–4.1) and 8.6 months (95% CI: 4.6–16.3) in the Doc/Pem arm and 5.6 months (95% CI: 4.2–9.1) and 14.1 months (95% CI: 5.1–not reached) in the G+Doc/Pem arm (Figure 2), respectively. A significant difference was observed in PFS (HR = 0.40, 95% CI: 0.16–0.99, p = 0.0391), but not in OS (HR = 0.49, 95% CI: 0.17–1.39, p = 0.169).

RR and DCR were 0% (95% CI: 0.0–28.5) and 27.3% (95% CI: 6.0–61.0) in the Doc/Pem arm, and 18.2% (95% CI: 2.3–51.8) and 54.5% (95% CI: 23.4–83.3) in the G+Doc/Pem arm. There were no significant differences in RR (p = 0.476) or DCR (p = 0.387) between the two arms (Table 3).

### TABLE 3  Objective response

|                          | Chemotherapy** arm (n = 11) | Gefitinib plus chemotherapy** arm (n = 11) | p-value* |
|--------------------------|----------------------------|---------------------------------------------|---------|
| CR                       | 0                          | 0                                           |         |
| PR                       | 0                          | 2 (18.2%)                                   |         |
| SD**                     | 3 (27.3%)                  | 4 (36.4%)                                   |         |
| PD                       | 7 (63.6%)                  | 1 (9.1%)                                    |         |
| NA                       | 1 (9.1%)                   | 4 (36.4%)                                   |         |
| Overall response rate (% 95% CI) | 0% (0.0–28.5) | 18.2% (2.3–51.8) | 0.476  |
| Disease control rate (%)  | 27.3% (6.0–61.0)           | 54.5% (23.4–83.3)                           | 0.387   |

**Abbreviation: CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease; NA, not applicable; CI, confidence interval; NA, not evaluated.

**Docetaxel or pemetrexed.

**Stable disease was confirmed and sustained for 6 weeks or longer.

*Fisher’s exact test was used, and p < 0.05 was significant.

### TABLE 4  Overall summary of adverse events

|                          | Chemotherapy** arm (n = 11) | Gefitinib plus chemotherapy** arm (n = 11) | p-value* |
|--------------------------|----------------------------|---------------------------------------------|---------|
| Severe AEs (≥ grade 3)   | 5 (45.5%)                  | 10 (90.9%)                                  | 0.032   |
| AEs led to dose reduction|                           |                                             |         |
| Docetaxel                | 2 (66.7%)                  | 3 (60.0%)                                   | 0.714   |
| Pemetrexed               | 1 (12.5%)                  | 0 (0.0%)                                    | 0.571   |

**Abbreviation: AE, adverse event; NA, not applicable.

**Docetaxel or pemetrexed.

*Fisher’s exact test was used, and p < 0.05 was significant.

### TABLE 5  Toxicities (≥ grade 3)

| Toxicity                | Chemotherapy** arm (n = 11) | Gefitinib plus chemotherapy** arm (n = 11) |
|-------------------------|-----------------------------|--------------------------------------------|
|                         | Docetaxel n = 3 (%)         | Pemetrexed n = 8 (%)                       | Docetaxel n = 5 (%) | Pemetrexed n = 6 (%) |
| Leucopenia              | 3 (100.0)                   | 0 (0.0)                                    | 5 (100.0)          | 2 (33.3)          |
| Neutropenia             | 3 (100.0)                   | 1 (12.5)                                   | 3 (60.0)           | 4 (66.7)          |
| Febrile neutropenia     | 1 (33.3)                    | 0 (0.0)                                    | 2 (40.0)           | 0 (0.0)           |
| Thrombopenia            | 0 (0.0)                     | 0 (0.0)                                    | 0 (0.0)            | 1 (16.7)          |
| Anemia                  | 0 (0.0)                     | 0 (0.0)                                    | 1 (20.0)           | 1 (16.7)          |
| Anorexia                | 0 (0.0)                     | 0 (0.0)                                    | 3 (60.0)           | 0 (0.0)           |
| Fatigue                 | 0 (0.0)                     | 0 (0.0)                                    | 3 (60.0)           | 1 (16.7)          |
| Diarrhea                | 0 (0.0)                     | 0 (0.0)                                    | 1 (20%)            | 0 (0.0)           |
| Infection               | 1 (33.3)                    | 0 (0.0)                                    | 0 (0.0)            | 1 (16.7)          |
| Others                  | 1 (33.3)                    | 1 (12.5)                                   | 2 (40%)            | 2 (33.3)          |

**Docetaxel or pemetrexed.

*Lymphopenia, elevated levels of alanine aminotransferase, hypoalbuminemia, and electrolyte abnormality.

### Efficacy

The median follow-up time was 8.8 months. The median PFS and OS were 1.6 months (95% CI: 1.2–4.1) and 8.6 months (95% CI: 4.6–16.3) in the Doc/Pem arm and 5.6 months (95% CI: 4.2–9.1) and 14.1 months (95% CI: 5.1–not reached) in the G+Doc/Pem arm (Figure 2), respectively. A significant difference was observed in PFS (HR = 0.40, 95% CI: 0.16–0.99, p = 0.0391), but not in OS (HR = 0.49, 95% CI: 0.17–1.39, p = 0.169).

RR and DCR were 0% (95% CI: 0.0–28.5) and 27.3% (95% CI: 6.0–61.0) in the Doc/Pem arm, and 18.2% (95% CI: 2.3–51.8) and 54.5% (95% CI: 23.4–83.3) in the G+Doc/Pem arm. There were no significant differences in RR (p = 0.476) or DCR (p = 0.387) between the two arms (Table 3).
Toxicity

Toxicity assessments were conducted on all treated patients ($n = 22$). Severe toxicities ($\geq$ grade 3) were observed in five patients (45.5%): leukopenia and neutropenia in three (27.3%) and four patients (36.4%), respectively, in the Doc/Pem arm. Lymph node infection, a grade 3 non-hematological toxicity, occurred in one patient. The frequency of severe hematological or nonhematological toxicities ($\geq$ grade 3) was significantly higher in the G + Doc/Pem arm (90.9% vs. 45.5%, $p = 0.032$). The severe toxicities ($\geq$ grade 3) in the G + Doc/Pem arm included leukopenia and neutropenia in 7 (63.6%) patients each and febrile neutropenia in two (18.2%) patients. Grade 3 toxicities, that is, anorexia and fatigue were observed in three and four patients (36.44%), respectively (Table 4). Three patients in each arm needed chemotherapy dose reductions due to treatment toxicity. Among patients receiving Doc, two out of three (66.7%) were in the Doc/Pem arm, while three out of five (60%) were in the G + Doc/Pem arm. One of the eight patients (12.5%) receiving Pem was in the Doc/Pem arm (Table 5). There were no treatment-related deaths in either arm (Figure 3).

DISCUSSION

This is the first randomized phase II study to assess the efficacy of continuing G with chemotherapy beyond PD in elderly patients with advanced EGFR-mutant NSCLC. However, this study ended in early July 2016 due to slow enrollment; the calculated sample size was not attained.

In this preliminary study, PFS was significantly longer in the G + Doc/Pem arm than in the Doc/Pem arm (HR = 0.40, 95% CI: 0.16–0.99, $p = 0.0391$). The median OS was approximately 14 months in the G + Doc/Pem arm, which was 6 months longer than that in the Doc/Pem arm. Furthermore, RR and DCR were higher in the G + Doc/Pem arm. However, the frequency of severe toxicities (AEs $\geq$ grade 3) was significantly higher in the G + Doc/Pem arm (90.9% vs. 45.5%, $p = 0.032$).

Chemotherapy has been suggested to improve the prognosis of patients and is recommended for EGFR-mutant NSCLC based on the findings of a subset analysis of previous phase III studies of EGFR-TKI.\textsuperscript{20,21} Platinum-doublet chemotherapies using a third-generation cytotoxic agent or Pem are recommended for patients <75 years with advanced NSCLC.\textsuperscript{22,23} Meanwhile, in elderly patients aged $\geq$75 years, carboplatin-doublet chemotherapies and a third-generation cytotoxic agent are recommended.\textsuperscript{24–26} Although platinum-based chemotherapies are recommended for healthy elderly patients aged $\geq$70 years, the number of these patients enrolled in clinical trials is limited.\textsuperscript{27} Many elderly patients do not tolerate chemotherapy well because of progressive reduction in organ function and the presence of comorbidities related to age. Most elderly patients are often not considered eligible for aggressive platinum-based chemotherapies and are usually treated with only a single cytotoxic agent.\textsuperscript{28} Therefore, we conducted this study using a single cytotoxic agent and targeted elderly patients aged $\geq$70 years.

The OS and RR in elderly patients with advanced NSCLC on a single third-generation agent as first-line treatment were approximately 5.0–14.0 months and 15%–20%, respectively.\textsuperscript{6,19,29} The efficacy of Pem as second-line...
treatment was equivalent to that of Doc in patients of various ages with advanced NSCLC. The Pem and Doc arms had the same median PFS and 1-year survival rate of 2.9 months and 29.7%, respectively. Small-scale studies on Pem in elderly patients with advanced NSCLC reported a PFS of 4–5 months and an RR of 15%. The safety profile and efficacy of treatment with Pem was similar to those of treatment with Doc in elderly patients with advanced NSCLC.

Some studies on combination therapy with G and chemotherapy in patients with NSCLC have been conducted. The phases I and II Iressa NSCLC Trial Assessing Combination Treatment (INTACT) study, which focused on EGFR mutation-unknown NSCLC did not demonstrate a benefit in the survival or response to combination therapy. However, combination therapy with G and chemotherapy was safe, with no significant unexpected AEs. In previous studies in elderly patients, a phase II trial on Doc combined with G reported a RR of 40% and a median PFS of 40% (95% CI: 26%–57%) and 6.9 months (95% CI: 3.95–7.8), respectively; this treatment was well-tolerated. A recent phase III study reported a significant efficacy of combination therapy with G and chemotherapy for EGFR-mutant advanced NSCLC. The primary endpoint, PFS, and OS were significantly longer with combination therapy, and a significant difference in RR was observed in the combination arm. The frequency of toxicities of ≥ grade 3 was significantly higher in the combination arm (51% vs. 25%, p ≤ 0.001).

Some researchers have reported the efficacy and utility of the continuation of EGFR-TKIs beyond PD with the addition of cytotoxic agents. However, there was no benefit in continuing G in combination with a platinum-doublet chemotherapy for EGFR-mutant NSCLC in the IMPRESS study. This study did not demonstrate the efficacy of continuing G in combination with chemotherapy after disease progression. Therefore, there is a need for clinical trials on combination therapy with the continuation of G and a single-agent chemotherapy beyond PD for elderly patients with advanced EGFR-mutant NSCLC.

In this study, the efficacy of G + Doc/Pem in terms of RR, PFS, and OS is similar to that of previous studies on DOC and Pem. Rapid exacerbation after one cycle of chemotherapy, such as disease progression, was observed in approximately 20% of the patients (2 of 11 patients) in the Doc/Pem arm.

The need for genotype profiling following rebiopsy in the management of EGFR-mutant NSCLC with acquired resistance to EGFR-TKIs has recently been suggested. EGFR-T790M mutation is a key oncogene profile and is responsible for the majority of EGFR-mutant NSCLC with acquired resistance to first- and second-generation EGFR-TKIs. Osimertinib was the first EGFR-TKI recommended for EGFR-T790M positive NSCLC. For patients who are T790M-negative at the time of acquired resistance, standard chemotherapy is recommended. However, the best timing to receive chemotherapy in T790M-negative patients is unclear.

In some studies which have reported the efficacy of continuation therapy with first-generation EGFR-TKIs including G and erlotinib beyond PD for advanced EGFR-mutant NSCLC, the continuation of EGFR-TKIs until symptomatic progression was beneficial for patients with EGFR-mutant NSCLC. Continuing EGFR-TKIs until symptomatic progression could be an alternative treatment for patients with T790M-negative NSCLC.

Our limited results suggest that the termination of G therapy and a switch to subsequent chemotherapy after the confirmation of PD based on the RECIST criteria is disadvantageous. Continued G treatment in combination with chemotherapy may be reasonable and beneficial in preventing acute exacerbation due to G withdrawal. In addition, combination chemotherapy may have a synergistic effect.

Rebiopsy is an indispensable technique for deciding the next treatment after progression of initial EGFR-TKI. Unfortunately, rebiopsy was not planned for in our study and there was no information on histological findings and mutation status before administration of study treatment. Chemotherapy is recommended in cases with unknown cause of initial EGFR-TKI resistance. Therefore, the results of our trial may show potential efficacy in limited cases in which rebiopsy test cannot be performed or sufficient samples are unavailable for rebiopsy testing analysis. Based on our limited results, combination chemotherapy with continuing gefitinib beyond PD may have potential benefit in limited elderly NSCLC without information on acquired resistance to gefitinib. However, further study is needed to assess the utility of that treatment among those population.

Based on the results of a scheduled interim analysis, this randomized study had important limitations including a poor accrual rate, short follow-up time, and premature end. Additionally, no molecular information in the enrolled patients with acquired resistance to G was obtained. We analyzed only the registered cases which lacked power to demonstrate our primary endpoint.

Further, our data lacked enough power to demonstrate the clinical utility of continuation of gefitinib as a single agent chemotherapy for second-line therapy because the study was not completed. Despite accruing less than half of the planned sample size, this study showed a significantly longer PFS with combination therapy. Our study findings are not generalizable due to the small sample size and incomplete accrual. However, this study provides a basis for considering combination therapy with the continuation of G and chemotherapy beyond PD for elderly patients with advanced EGFR-mutant NSCLC.

In conclusion, combination therapy with the continuation of G and chemotherapy showed a better efficacy but was also associated with an increased toxicity in elderly Japanese patients with EGFR-mutant NSCLC.

ACKNOWLEDGMENTS
We thank the patients, their families, and investigators for their support and participation in this study. We are grateful
to the office staff and members of the Japan-Multinational Trial Organization for their contributions.

CONFLICT OF INTEREST
This study was supported by the Japan-Multinational Trial Organization and was funded by AstraZeneca (grant no. ISSIRE0072). K.A received honoraria from AstraZeneca, M.A. received grant from Kyowa Kirin Co. Ltd. for work outside the submitted study. T.Y. and M.M. received honoraria from AstraZeneca, H.Y. received a lecture fee from AstraZeneca and Eli Lilly. S.A. reported personal fees from AstraZeneca, MSD, Eli Lilly, Chugai, Ono, Taiho, Boehringer Ingelheim, Pfizer, Bristol-Myers Squib, Hisamitsu, and Kyowa Hakko Kirin, and received grants from AstraZeneca, MSD, Eli Lilly, Chugai, Ono, Taiho, Boehringer Ingelheim, Pfizer, F. Hoffmann-La Roche, and Bristol-Myers Squib. All other authors had no conflict of interests to declare.

ORCID
Kazuhiro Asami https://orcid.org/0000-0002-5077-0826
Fumitaka Ogushi https://orcid.org/0000-0003-3525-3457

REFERENCES
1. Barta JA, Powell CA, Wisnivesky JP. Global epidemiology of lung cancer. Ann Glob Health. 2019;85:8.
2. Death rates fall for 8 of 10 top causes; Alzheimer’s up to no. 6. Hosp Health Netw. 2008;82:127.
3. Travis WD, Rekhtman N, Geisinger KR, Asamura H, Brambilla E, et al. Pathologic diagnosis of advanced lung cancer based on small biopsies and cytology: a paradigm shift. J Thorac Oncol. 2010;5:411–4.
4. Yamaguchi T, Nishiura H. Predicting the epidemiological dynamics of lung cancer in Japan. J Clin Med. 2019;8:326.
5. Takayuki N, Keiko T, Junji T, Yoshiho K, Nobuyo T, Tadaaki Y, et al. Advanced non-small-cell lung cancer in elderly patients: patient features and therapeutic management. Biomed Res Int. 2018;2018:8202971.
6. Kudoh S, Takeda K, Nakagawa K, Takada M, Katakami N, Matsui K, et al. Phase III study of docetaxel compared with vinorelbine in elderly patients with advanced non-small-cell lung cancer: results of the West Japan thoracic oncology group trial (WJTOG 9904). J Clin Oncol. 2006;24:3657–63.
7. Weiss GI, Langer C, Rosell R, Hanna N, Shepherd F, Einhorn LH, et al. Elderly patients benefit from second-line cytotoxic chemotherapy: a subset analysis of a randomized phase III trial of pemetrexed compared with docetaxel in patients with previously treated advanced non-small-cell lung cancer. J Clin Oncol. 2006;24:4405–11.
8. Gridelli C, Brodowicz T, Langer CJ, Peterson P, Islam M, Guba SC, et al. Pemetrexed therapy in elderly patients with good performance status: analysis of two phase III trials of patients with nonsquamous non-small-cell lung cancer. Clin Lung Cancer. 2012;13:340–8.
9. Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009;361:947–57.
10. Mitsudomi T, Miura S, Yatabe Y, Negoro S, Okamoto I, Tsurutani J, et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol. 2010;11:121–8.
11. Maemondo M, Inoue A, Kobayashi K, Sugawara S, Oizumi S, Isobe H, et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med. 2010;362:2380–8.
12. Maemondo M, Minegishi Y, Inoue A, Kobayashi K, Harada M, Okinaga S, et al. First-line gefitinib in patients aged 75 or older with advanced non-small cell lung cancer harboring epidermal growth factor receptor mutations: NEJ003 study. J Thorac Oncol. 2012;7:1417–22.
13. Asami K, Koizumi T, Hirai K, Amemehsa S, Tsukada A, Morozumi N, et al. Gefitinib as first-line treatment in elderly epidermal growth factor receptor-mutated patients with advanced lung adenocarcinoma: results of a Nagano lung cancer research group study. Clin Lung Cancer. 2011;12:387–92.
14. Manegold C, Gatzemeier U, Buchholz E, Smith RP, Fandi A. A pilot trial of gefitinib in combination with docetaxel in patients with locally advanced or metastatic non-small-cell lung cancer. Clin Lung Cancer. 2005;6:343–9.
15. Yoshishita N, Okishio K, Mitsuka S, Kimura T, Kawaiuchi T, Kobayashi M, et al. Prospective assessment of continuation of erlotinib or gefitinib in patients with acquired resistance to erlotinib or gefitinib followed by the addition of pemetrexed. J Thorac Oncol. 2013;8:96–101.
16. Chaft JE, Oxnard GR, Sima CS, Kris MG, Miller VA, Riel GJ. Disease flare after tyrosine kinase inhibitor discontinuation in patients with EGFR-mutant lung cancer and acquired resistance to erlotinib or gefitinib: implications for clinical trial design. Clin Cancer Res. 2011;17:6298–303.
17. Asami K, Okuma T, Hirashima T, Kawahara M, Atagi S, Kawaiuchi T, et al. Continued treatment with gefitinib beyond progression disease benefits patients with activating EGFR mutations. Lung Cancer. 2013;79:276–82.
18. Schoenfeld D. The asymptotic properties of nonparametric tests for comparing survival distributions. Biometrika. 1981;68:316–9.
19. Gridelli C, Perrone F, Gallo C, Cigolari S, Rossi A, Piantedosi F, et al. Chemotherapy for elderly patients with advanced non-small-cell lung cancer: the multicenter Italian lung cancer in the elderly study (MILES) phase III randomized trial. J Natl Cancer Inst. 2003;95:362–72.
20. Inoue A, Kobayashi K, Maemondo M, Sugawara S, Oizumi S, Isobe H, et al. Updated overall survival results from a randomized phase III trial comparing gefitinib with carboplatin-paclitaxel for chemonaive non-small-cell lung cancer with sensitive EGFR gene mutations (NEJ002). Ann Oncol. 2013;24:54–9.
21. Yoshioka H, Shimokawa M, Seto T, Morita S, Yatabe Y, Okamoto I, et al. Final overall survival results of WTJOG3405, a randomized phase III trial comparing gefitinib versus cisplatin with docetaxel as the first-line treatment for patients with stage IIIIB/IV or postoperative recurrent EGFR mutation-positive non-small-cell lung cancer. Ann Oncol. 2019;30:1978–84.
22. Ohe Y, Ohashi Y, Kubota K, Tamura T, Nakagawa K, Negoro S, et al. Randomized phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non-small-cell lung cancer: Four-Arm Cooperative Study in Japan. Ann Oncol. 2007;18:317–23.
23. Scagliotti GV, Parikh P, von Pawel J, Biesma B, Vansteenkiste J, Manegold C, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol. 2008;26:3543–51.
24. Abe T, Takeda K, Ohe Y, Kudoh S, Ichinose Y, Okamoto H, et al. Randomized phase III trial comparing weekly docetaxel plus cisplatin versus docetaxel monotherapy every 3 weeks in elderly patients with advanced non-small-cell lung cancer: the intergroup trial JCOG0803/WJOG4307L. J Clin Oncol. 2015;33:575–81.
25. Okamoto I, Nokihara H, Nomura S, Niho S, Sugawara S, Horinouchi H, et al. Comparison of carboplatin plus pemetrexed followed by maintenance pemetrexed with docetaxel monotherapy in elderly patients with advanced nonsquamous non-small-cell lung cancer: a phase 3 randomized clinical trial. JAMA Oncology. 2020;6:196828.
26. Quoix E, Zalcman G, Oster JP, Westeel V, Pichon E, Lavolé A, et al. Carboplatin and weekly paclitaxel doublet chemotherapy compared with monotherapy in elderly patients with advanced non-small-cell lung cancer: IFCT-0501 randomised, phase 3 trial. Lancet. 2011;378:1079–88.
27. Gridelli C, Aapro M, Ardizzoni A, Balducci L, de Marinis F, Kelly K, et al. Treatment of advanced non-small-cell lung cancer in the elderly: results of an international expert panel. J Clin Oncol. 2005;23:3125–37.

28. Takayuki N, Keiko T, Junji U, Yoshiko K, Nobuyo T, Tadaaki Y, et al. Advanced non-small-cell lung cancer in elderly patients: patient features and therapeutic management. Biomed Res Int. 2018;2018:820971.

29. Frasci G, Lorusso V, Panella N, Comella P, Nicolella G, Bianco A, et al. Gemcitabine plus vinorelbine versus vinorelbine alone in elderly patients with advanced non-small-cell lung cancer. J Clin Oncol. 2000;18:2529–36.

30. Hanna N, Shepherd FA, Fossella FV, Pereira JR, de Marinis F, von Pawel J, et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol. 2004;22:1589–97.

31. Fukuda M, Kitaaki T, Ogawa D, Ichiki M, Mukae H, Maruyama R, et al. Randomized phase II study of pemetrexed or pemtrexed plus bevacizumab for elderly patients with previously untreated non-squamous non-small cell lung cancer: results of the lung oncology group in Kyushu (LOGIK1201). Lung Cancer. 2019;132:1–8.

32. Hata A, Katakami N, Hattori Y, Tanaka K, Fujita S, Kotani Y, et al. Pemetrexed monotherapy for chemonaive elderly (aged ≥80) patients with non-squamous non-small cell lung cancer: results from combined analysis of two single arm phase II studies (HANSHIN002 and 003). Cancer Chemother Pharmacol. 2017;79:689–95.

33. Giaccone G, Herbst RS, Manegold C, Scagliotti G, Rosell R, Miller V, et al. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial—INTACT 1. J Clin Oncol. 2004;22:777–84.

34. Herbst RS, Giaccone G, Schiller JH, Natale RB, Miller V, Manegold C, et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial—INTACT 2. J Clin Oncol. 2004;22:785–94.

35. Simon GR, Extermann M, Chiappori A, Williams CC, Begum M, Kapoor R, et al. Phase 2 trial of docetaxel and gefitinib in the first-line treatment of patients with advanced nonsmall-cell lung cancer (NSCLC) who are 70 years of age or older. Cancer. 2008;12:2021–9.

36. Noronha V, Patil VM, Joshi A, Menon N, Chougule A, Mahajan A, et al. Gefitinib versus gefitinib plus pemetrexed and carboplatin chemotherapy in EGFR-mutated lung cancer. J Clin Oncol. 2020;38:124–36.

37. Goldberg SB, Oxnard GR, Digumarthy S, Muzikansky A, Jackman DM, Lennes JT, et al. Chemotherapy with erlotinib or chemotherapy alone in advanced non-small cell lung cancer with acquired resistance to EGFR tyrosine kinase inhibitors. Oncologist. 2013;18:1214–20.

38. Soria JC, Wu YL, Nakagawa K, Kim SW, Yang JJ, Ahn MJ, et al. Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation-positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): a phase 3 randomised trial. Lancet Oncol. 2015;16:990–8.

39. Wu SG, Liu YN, Tsai MF, Chang YL, Yu CJ, Yang PC, et al. The mechanism of acquired resistance to irreversible EGFR tyrosine kinase inhibitor-afatinib in lung adenocarcinoma patients. Oncotarget. 2016;7:12404–13.

40. Goss G, Tsai CM, Shepherd FA, Bazhenova L, Lee JS, Chang GC, et al. Osimertinib for pretreated EGFR Thr790Met-positive advanced non-small-cell lung cancer (AURA2): a multicentre, open-label, single-arm, phase 2 study. Lancet Oncol. 2016;17:1643–52.

41. Mok TS, Wu YL, Papadimitrakopoulou VA. Osimertinib in EGFR T790M-positive lung cancer. N Engl J Med. 2017;376:1993–4.

42. Yang JJ, Chen HJ, Yan HH, Zhang XC, Zhou Q, Su J, et al. Clinical modes of EGFR tyrosine kinase inhibitor failure and subsequent management in advanced non-small cell lung cancer. Lung Cancer. 2013;79:33–9.

43. Park K, Yu CJ, Kim SW, Lin MC, Sriuranpong V, Tsai CM, et al. First-line erlotinib therapy until and beyond response evaluation criteria in solid tumors progression in Asian patients with epidermal growth factor receptor mutation-positive non-small-cell lung cancer: the ASPIRATION study. JAMA Oncol. 2016;2:305–12.

44. Lim SW, Park S, Kim Y, Cho JH, Park SE, Lee H, et al. Continuation of gefitinib beyond progression in patients with EGFR mutation-positive non-small-cell lung cancer: a phase II single-arm trial. Lung Cancer. 2018;124:293–7.

45. Gridelli C, Langer C, Maione P, Rossi A, Schild SE. Lung cancer in the elderly. J Clin Oncol. 2007;25:1898–907.

How to cite this article: Asami K, Ando M, Nishimura T, Yokoi T, Tamura A, Minato K, et al. A randomized phase II study of docetaxel or pemetrexed with or without the continuation of gefitinib after disease progression in elderly patients with non-small cell lung cancer harboring EGFR mutations (JMTO LC12-01). Thorac Cancer. 2022;13(12):1827–36. https://doi.org/10.1111/1759-7714.14465